{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T10:12:28Z","timestamp":1789726348221,"version":"4.0.1"},"reference-count":16,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["COPD"],"DOI":"10.2147\/copd.s307160","type":"journal-article","created":{"date-parts":[[2021,4,22]],"date-time":"2021-04-22T00:27:28Z","timestamp":1619051248000},"page":"1137-1148","source":"Crossref","is-referenced-by-count":44,"title":["A Dose-Ranging Study of the Novel Inhaled Dual PDE 3 and 4 Inhibitor Ensifentrine in Patients with COPD Receiving Maintenance Tiotropium Therapy"],"prefix":"10.2147","volume":"Volume 16","author":[{"given":"Gary T","family":"Ferguson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1697-9036","authenticated-orcid":true,"given":"Edward M","family":"Kerwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara","family":"Rheault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Bengtsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2542-6011","authenticated-orcid":true,"given":"Kathleen","family":"Rickard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2021,4]]},"reference":[{"key":"ref1","unstructured":"World Health Organization. Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/the-top-10-causes-of-death. Accessed April 12, 2021."},{"key":"ref2","unstructured":"Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease; 2020. Available from: https:\/\/goldcopd.org\/gold-reports\/. Accessed April 12, 2021."},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1016\/S0140-6736(17)30188-5","volume":"389","author":"Vestbo","year":"2017","journal-title":"Lancet"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1183\/09031936.00124013","volume":"43","author":"Mahler","year":"2014","journal-title":"Eur Respir J"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1111\/j.1476-5381.2009.00170.x","volume":"157","author":"Banner","year":"2009","journal-title":"Br J Pharmacol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1111\/j.1476-5381.1992.tb14451.x","volume":"106","author":"De Boer","year":"1992","journal-title":"Br J Pharmacol"},{"key":"ref7","volume-title":"Phosphodiesterases as Drug Targets. Handbook of Experimental Pharmacology","year":"2011"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/S0140-6736(09)61255-1","volume":"374","author":"Calverley","year":"2009","journal-title":"Lancet"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"A4529","DOI":"10.1164\/rccm.201812-2345LE","volume":"199","author":"Singh","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"ref10","unstructured":"DALIRESP\u00ae (roflumilast) [prescribing information]. Wilmington. DE: AstraZeneca Pharmaceuticals LP; January, 2018."},{"key":"ref11","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.pharmthera.2019.02.002","volume":"197","author":"Zuo","year":"2019","journal-title":"Pharmacol Ther"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s12931-020-1307-4","volume":"21","author":"Singh","year":"2020","journal-title":"Respir Res"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1801074","DOI":"10.1183\/13993003.01074-2018","volume":"52","author":"Singh","year":"2018","journal-title":"Eur Respir J"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/S2213-2600(13)70187-5","volume":"1","author":"Franciosi","year":"2013","journal-title":"Lancet Respir Med"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1164\/ajrccm.163.5.2101039","volume":"163","author":"Pauwels","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/1465-9921-12-18","volume":"12","author":"Rennard","year":"2011","journal-title":"Respir Res"}],"container-title":["International Journal of Chronic Obstructive Pulmonary Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=68783","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=68783","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,22]],"date-time":"2021-04-22T00:27:49Z","timestamp":1619051269000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/a-dose-ranging-study-of-the-novel-inhaled-dual-pde-3-and-4-inhibitor-e-peer-reviewed-fulltext-article-COPD"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":16,"URL":"https:\/\/doi.org\/10.2147\/copd.s307160","relation":{},"ISSN":["1178-2005"],"issn-type":[{"value":"1178-2005","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4]]}}}